Prof. Shakeel Qureshi is the Principal Investigator (PI) for the CE Mark certification clinical trial in Europe, the first phase of the clinical trials of which involved 6 locations, and 80 to 100 patients across Europe, including a few locations outside of the continent. This is the first formal set of clinical trials in multiple locations across Europe that used China-made transcatheter valves.
Venus Medtech is fully dedicated to the research and development of medical instruments for cardiac valves that require minimally invasive treatment. The firm has twice been the first worldwide to produce the models for new valve systems: the pre-loading transcatheter valve system and the transcatheter self-expanding pulmonary valve system.
Venus Medtech (Hangzhou) Inc., located in Hangzhou National Hi-tech Development Zone (Binjiang District), focuses their R&D on internationally advanced artificial valve systems with commercial applications and has gone a long way in satisfying the need for such products both in China and around the world.
For more information, please visit http://en.venusmedtech.com/
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/venus-medtechs-transcatheter-pulmonary-valve-debuts-in-europe-marking-the-start-of-global-clinical-trial-300329923.html
SOURCE Venus Medtech (Hangzhou) Inc.